Pharmafile Logo
Pharmafocus logo
Advanced Search

Sales and Marketing

Showing 15 posts of 11524 posts found.

AstraZeneca’s AZD3480 progresses in ADHD

July 11, 2009 Sales and Marketing ADHD, Alzheimer's, Alzheimer's ADHD, AstraZeneca

 AstraZeneca is to progress its AZD3480 (TC-1734) for attention deficit/hyperactivity disorder (ADHD) and has agreed to make a $10 million …
News

WHO gives Cervarix green light for use in developing nations

July 10, 2009 Research and Development, Sales and Marketing Cervarix, vaccines

News

NICE to reconsider GSK’s Tyverb

July 9, 2009 Research and Development, Sales and Marketing GSK, NICE, Tyverb

NICE is to reconsider Tyverb under its new lenient approach for end-of-life drugs, after GSK appealed its previous rejection of …
News

Victoza launched in UK

July 9, 2009 Sales and Marketing Victoza, diabetes

Novo Nordisk this week launched its much-anticipated type II diabetes treatment Victoza in the UK. Victoza (liraglutide) is the first …
News

Writing on the wall for ‘pay to delay’ generics deals

July 9, 2009 Research and Development, Sales and Marketing FDA, US, generics

Deals allowing US pharma companies to pay generics competitors to delay the launch of rival products should be ended, according …
News

Genzyme’s woes are a boost for Shire and Protalix

July 9, 2009 Research and Development, Sales and Marketing FDA, Genzyme, US

The contamination problems at a plant used by Genzyme to manufacture a drug for Gaucher disease have prompted the US …
News
Eisai's new European HQ in Hatfield, Hertfordshire

Eisai opens new European HQ in the UK

July 8, 2009 Manufacturing and Production, Research and Development, Sales and Marketing Eisai, Europe, HQ

Eisai has officially opened its new European headquarters in the UK, its biggest-ever single capital investment that will bring teams …
Feature

Sanofi moves to quell Lantus safety concerns

July 7, 2009 Research and Development, Sales and Marketing Lantis, Sanofi-Aventis, diabetes

Sanofi-Aventis has rejected claims of a possible connection between its diabetes treatment Lantus and cancer. The possible link was reported …
News

Depression warnings for Chantix and Zyban

July 7, 2009 Research and Development, Sales and Marketing Chantix, FDA, US, drug safety

Pfizer and GSK's smoking cessations drugs will have to carry strong warnings of depression and other mental health adverse events …
News

PM Soc’s Digital Media Awards to highlight pioneering work

July 7, 2009 Sales and Marketing digi, pm society

UK pharma companies and agencies are being invited to submit entries to the industry's first-ever digital media awards, which aim …
News
VasellaWEB

Vasella: on leadership

July 7, 2009 Sales and Marketing Novartis, Vasella, leadership, management

Novartis’ chief executive and chairman talks to McKinsey about his personal approach to management and leadership, and examines subjects including …
Feature

Roche’s ABPI exit – a deliberate snub?

July 3, 2009 Research and Development, Sales and Marketing ABPI, Roche

 By Nicola O’BrienRoche is yet to explain its controversial exit from the ABPI, but the company seems determined to make …
News

HRA Pharma opens UK subsidiary

July 3, 2009 Sales and Marketing HRA Pharma

Privately-owned French drug maker HRA Pharma, which specialises in reproductive health and endocrinology, has opened its first UK subsidiary. The …
News

Asia Pacific vaccines market requires flexible, targeted portfolios

July 2, 2009 Research and Development, Sales and Marketing Asia, vaccines

Spanning one third of the globe's circumference and home to more than half of the world's population, the Asia Pacific …
News

Onglyza and Cimzia recommended by CHMP

July 2, 2009 Research and Development, Sales and Marketing AZ, BMS, EMEA, Europe, Ongylza

Bristol-Myers Squibb andAstraZeneca's type II diabetes treatment Onglyza is among the brands to have received positive opinions from the Committee …
News
The Gateway to Local Adoption Series

Latest content

Siemens Healthineers opens 10m euro R&D centre for laboratory equipment in Ireland

February 19, 2026

Everdrone announces new board of directors to drive expansion

February 19, 2026

Regeneron announces presentations of new data on Eylea HD for retinal disease

February 18, 2026

Indegene completes acquisition of Cake Health

February 18, 2026

Gedeon Richter UK acquires rights to schizophrenia treatment Reagila from Recordati Pharmaceuticals

February 17, 2026